Hypermarcas (OTCMKTS:HYPMY) Shares Shorted: Short Interest Up 82.1% in September

Hypermarcas (OTCMKTS:HYPMY) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totaling 4,266 shares, a growth of 82.1% from the September 15th total of 2,343 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 20,164 shares, the short-interest ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy”.

Hypermarcas Stock Performance

HYPMY traded down $0.03 during trading hours on Friday, hitting $5.03. 259 shares of the stock were exchanged, compared to its average volume of 46,670. The stock has a 50-day simple moving average of $4.55 and a 200-day simple moving average of $4.40. Hypermarcas has a 12 month low of $3.72 and a 12 month high of $5.77. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of 10.05 and a beta of 0.65. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a net margin of 19.77% and a return on equity of 12.68%. Analysts anticipate that Hypermarcas will post 0.51 earnings per share for the current year.

About Hypermarcas

Hypermarcas SA was a Brazilian consumer healthcare company that developed, manufactured and marketed pharmaceutical and healthcare products. Its portfolio included over-the-counter medicines, prescription products, vitamins and other consumer health brands sold through pharmacies and retail channels.

The company was historically associated with well-known Brazilian brands such as Benegrip, Biotônico Fontoura, Doril, Engov and Epocler. Hypermarcas also previously operated in personal care, beauty, household cleaning and other consumer categories, but divested many of those businesses as it concentrated on pharmaceuticals and healthcare.

In 2018, Hypermarcas changed its corporate name to Hypera SA, adopting the Hypera Pharma identity.